From GlobeNewswire: 2025-05-08 07:15:00

Royalty Pharma plc reported a strong first quarter of 2025 with a 17% growth in Portfolio Receipts to $839 million and a 12% growth in Royalty Receipts to $788 million. They also raised their full year 2025 guidance for Portfolio Receipts to $2,975 to $3,125 million. The company repurchased over $700 million of its Class A ordinary shares and expanded their development-stage portfolio with a partnership with Biogen for R&D funding.

Key developments in the portfolio included positive clinical and regulatory updates for various products, such as Johnson & Johnson’s Tremfya receiving FDA and EC approval in Crohn’s disease and Roche initiating a Phase 3 program for trontinemab in Alzheimer’s disease. Royalty Pharma also entered into an R&D funding partnership with Biogen for litifilimab, a Phase 3 development for lupus.

Royalty Pharma’s liquidity and capital resources were strong with $1.1 billion in cash and cash equivalents as of March 31, 2025. They completed the sale of MorphoSys Development Funding Bonds for $511 million, providing additional flexibility for their capital allocation strategy. The company also repurchased approximately 23 million Class A ordinary shares for $723 million during the first quarter of 2025.

The company provided guidance for full year 2025, expecting Portfolio Receipts to be between $2,975 million and $3,125 million, representing growth of 6% to 12%. This guidance excludes the impact of the internalization transaction announced in January 2025 and assumes no additional debt financing for the year. Interest paid is anticipated to be approximately $260 million in 2025. Royalty Pharma is focused on maximizing shareholder value and growth through strategic capital deployment and strong portfolio performance.



Read more at GlobeNewswire:: Royalty Pharma Reports First Quarter 2025 Results